London City manager Jocelyn Precheur has said he is optimistic her side can close the gap on Arsenal in time despite losing 4-1 in their debut Women's Super League (WSL) fixture. It was a productive ...

The Women's Super League (WSL) summer transfer window closed at 11 p.m. BST (6 ET) on Thursday and came in two phases, with July's Euro 2025 tournament causing a period of quietness before it all ...

EDITOR’S NOTE: Chief Medical Correspondent Dr. Sanjay Gupta’s new book, “It Doesn’t Have to Hurt,” is available now. Watch “Dr. Sanjay Gupta Reports: It Doesn’t Have to Hurt.” at 9 p.m. ET on ...

Ed Mowery, the founder and lead singer of a death metal band, suffered unfathomable pain for decades: "It was 24/7, 365," he said, likening it to "lightning bolt razor snakes in my legs and nerve pain ...

A brain implant that detects when someone is in pain and responds with deep brain stimulation has helped relieve people from previously untreatable chronic pain – with one participant even becoming ...

The condition is hard to treat. But moving can help, if you do it right. Ask Well The condition is hard to treat. But moving can help, if you do it right. Credit...Joyce Lee for The New York Times ...

A guitarist in a death metal band was one of several people who found that personalized deep brain stimulation eased their pain and helped them reduce pain medication. A guitarist in a death metal ...

Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase ...

Almost everyone has pain sometimes. It might start as a twinge in your back, a dull ache in your knee, a tingling on the bottoms of your feet. Maybe you slept funny, or hoisted a full bag of groceries ...

Dr. Adriaan Louw has heard the term "pain revolution" before. The physical therapist and scientist has been researching chronic pain for more than 30 years. Over the decades, he has witnessed the rise ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...